Literature DB >> 14633370

Association between antecedent intravenous antimicrobial exposure and isolation of vancomycin-resistant enterococci.

L S Chavers1, S A Moser, E Funkhouser, W H Benjamin, P Chavers, A M Stamm, K B Waites.   

Abstract

Vancomycin-resistant enterococci (VRE) have become important causes of nosocomial infections. This study evaluated the association between a variety of intravenous antimicrobial exposures and the isolation of VRE using two control groups: (1) a vancomycin-susceptible enterococci (VSE) group, to assess factors associated with development of VRE, and (2) a nonenterococci control group, to assess factors associated with positive cultures for enterococci without regard to vancomycin resistance. After adjusting for the effect of other antimicrobials, time at risk, and patient morbidity, compared to vancomycin-susceptible enterococci controls, exposures to imipenem (OR = 4.9, 95% CI = 1.6-14.1) and ceftazidime (OR = 2.6, 95% CI = 1.1-6.1) were significant predictors of VRE. When compared to nonenterococci controls, exposures to ampicillin (OR = 20.1, 95% CI = 1.5-263.1) and imipenem (OR = 5.1, 95% CI = 1.5-17.1) were significantly associated with VRE. Neither piperacillin nor vancomycin was associated with VRE compared to either control group. This study offers further evidence that the replacement of broad-spectrum cephalosporins by extended-spectrum penicillins, specifically piperacillin, may be effective in reducing VRE.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14633370     DOI: 10.1089/107662903322541928

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  5 in total

Review 1.  Antibiotics and gastrointestinal colonization by vancomycin-resistant enterococci.

Authors:  L B Rice
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

2.  A guide to antibiotics for the interventional radiologist.

Authors:  Ali Zarrinpar; Robert K Kerlan
Journal:  Semin Intervent Radiol       Date:  2005-06       Impact factor: 1.513

3.  Outbreak of vancomycin-resistant enterococcus colonization among pediatric oncology patients.

Authors:  Sheila M Nolan; Jeffrey S Gerber; Theoklis Zaoutis; Priya Prasad; Susan Rettig; Kimberly Gross; Karin L McGowan; Anne F Reilly; Susan E Coffin
Journal:  Infect Control Hosp Epidemiol       Date:  2009-04       Impact factor: 3.254

4.  Epidemiology of vancomycin-resistant Enterococcus faecalis: a case-case-control study.

Authors:  Kayoko Hayakawa; Dror Marchaim; Mohan Palla; Uma Mahesh Gudur; Harish Pulluru; Pradeep Bathina; Khaled Alshabani; Aditya Govindavarjhulla; Ashwini Mallad; Deepika Reddy Abbadi; Deepti Chowdary; Hari Kakarlapudi; Harish Guddati; Manoj Das; Naveen Kannekanti; Praveen Vemuri; Rajiv Doddamani; Venkat Ram Rakesh Mundra; Raviteja Reddy Guddeti; Rohan Policherla; Sarika Bai; Sharan Lohithaswa; Shiva Prasad Shashidharan; Sowmya Chidurala; Sreelatha Diviti; Krishna Sukayogula; Melwin Joseph; Jason M Pogue; Paul R Lephart; Emily T Martin; Michael J Rybak; Keith S Kaye
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

5.  Case-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia.

Authors:  Agnes Loo Yee Cheah; Trisha Peel; Benjamin P Howden; Denis Spelman; M Lindsay Grayson; Roger L Nation; David C M Kong
Journal:  BMC Infect Dis       Date:  2014-06-28       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.